NCT00458159终止1 期
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Celgene
- 入组人数
- 34
- 试验地点
- 7
- 主要终点
- Maximum Tolerated Dose of CC-11006
研究概览
简要总结
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: CC-11006 (Drug)
结局指标
主要结局
Maximum Tolerated Dose of CC-11006
时间窗: 2 cohorts
次要结局
- Safety of CC-11006-MDS-001(Ongoing basis)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic CancerAcinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerNCT01835041Wake Forest University Health Sciences21
已完成
1 期
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple MyelomaMultiple MyelomaNCT02157636Constellation Pharmaceuticals30
已完成
1 期
Phase I study of Continuous Hyperfractionated Accelerated RadioTherapy - Escalated Doseon-small cell lung cancer (NSCLC)Malignant neoplasm of bronchus and lungCancerISRCTN45918260Sheffield Teaching Hospitals NHS Foundation Trust (UK)18
招募中
1 期
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04472858Suzhou Zelgen Biopharmaceuticals Co.,Ltd30
已完成
1 期
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesGastrointestinal Stromal TumorsAdvanced Systemic MastocytosisAdvanced CancersNCT02571036Deciphera Pharmaceuticals, LLC282